Greenway Therapeutix® is Exhibiting at the Prestigious Maui Derm Meeting

Maui, HI, January 25, 2020 – Greenway Therapeutix®, Inc., a Biopharmaceutical company dedicated to the research and development of medical grade cannabinoid therapeutics utilizing nanotechnology, was exhibiting at the prestigious Maui Derm Conference in Wailea, Maui. 

Each year Maui Derm’s lectures, panel discussions and workshops are designed to bridge the ever-widening knowledge gap by providing an in-depth look at topics vital to the practice of dermatology. The diverse and expert faculty present in-depth, cutting edge materials covering a wide array of medical, cosmetic, coding/billing and CLIA certification topics in dermatology.

Dr. George Martin, who is the founder and Program Director of the Maui Derm conference, indicated that he is excited to have Greenway Therapeutix® participating as a first-time supporter of the meeting. He also indicated that there is a large potential for the future of CBD research, education and medical products in Dermatology.

The company’s CEO, Dr. Michael Milane, CSO, Dr. Dan Siegel and Scientific Advisory Board members, Dr. Todd Schlesinger and Dr. Neal Bhatia, were present at the meeting and the Greenway booth throughout the conference to address a high number of questions from over 500+ clinicians in attendance. There was a lot of interest in current data on Canno Cream™ and when products will become available in US offices.

About Greenway Therapeutix

Greenway Therapeutix® is a medically focused Biopharmaceutical company created by doctors and scientists, dedicated to the research and development of medical-grade cannabinoid therapeutic products, while utilizing cutting edge nanotechnology in their skin delivery. High-Potency Cannabidiol (CBD) Therapeutic products are currently in clinical development and testing for the evaluation of multiple inflammatory skin conditions.

Canno Cream™ is the first Dermatology developed and Medical Grade 99% CBD cream with a novel nano CBD formulation, designed to provide potential relief with positive data for a multitude of inflammatory skin conditions. The product is a Cosmeceutical and is only intended for symptom relief and not FDA approved or indicated for any disease conditions.

For more information, visit

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.